Propensity score matching/reweighting analysis comparing intravenous golimumab to infliximab for ankylosing spondylitis using data from the GO-ALIVE and ASSERT trials.

Treatment with GOL IV was also associated with greater numerical improvements from baseline in BASFI score than IFX, though these changes did not reach statistical significance or the MCII cutoff of 0.6 for BASFI in patients with active AS [ 33 ].

also in 111,027 other papers